Roche Pipeline Potency Validates No-Merger Stance, Company Says
Executive Summary
Roche has the third largest pipeline of new molecular entities in development in the drug industry, the company maintained during an R&D day in New York City May 6
You may also be interested in...
Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol
Pharmaceutical companies marketing primary care products are unlikely to see a significant return on their investment, Bristol-Myers Squibb CFO Andrew Bonfield declared June 10
Primary Care Rx Market Offers Second-Rate Return On Investment – Bristol
Pharmaceutical companies marketing primary care products are unlikely to see a significant return on their investment, Bristol-Myers Squibb CFO Andrew Bonfield declared June 10
M&A Will Accelerate In European Markets, Slow Down In U.S. – Schering CEO
The Rx drug industry can expect to see much more merger activity among European companies, while consolidation in the U.S. essentially has tapered off, Schering-Plough CEO Fred Hassan said